3D MEDICINES-B(01244.HK)香港發售股份獲小幅超額認購 發售價每股24.98港元
格隆匯12月14日丨3D MEDICINES-B(01244.HK)發佈公吿,公司全球發售1635萬股股份,其中香港發售股份163.5萬股,國際發售股份1471.5萬股;發售價已釐定為每股發售股份24.98港元,每手買賣單位500股;中金公司及中信建投國際為聯席保薦人;預期股份將於2022年12月15日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲小幅超額認購。接獲合共2805份有效申請,認購合共976.25萬股,相當於香港公開發售項下初步可供認購發售股份總數約5.97倍。國際發售項下初步提呈發售的國際發售股份已獲小幅超額認購,相當於國際發售項下初步可供認購發售股份總數約1.26倍(於任何超額配股權獲行使前)。按發售價每股24.98港元計算,基石投資者已合共認購939.15萬股發售股份。
按發售價每股24.98港元計算,公司將收取的全球發售所得款項淨額估計約為2.511億港元(於任何超額配股權獲行使前)。公司擬將所得款項淨額約90%將主要用於產品和候選藥物的研發、監管備案及商業化;以及約10%所得款項淨額將用於一般企業及營運資金用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.